SAB Biotherapeutics, Inc. (SABS) Stock Analysis & Investment Frameworks
SAB Biotherapeutics, Inc. (SABS) stock analysis on Invetso. Review SAB Biotherapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
SAB Biotherapeutics, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
SAB Biotherapeutics, Inc. Key Financial Metrics
- Market Cap: $258.40M
- Revenue: $N/A
- P/E Ratio: 18.93
- ROE: -6.74%
- ROIC: -31.62%
- Dividend Yield: N/A
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.